The CBX8 Knockout A-549 Polyclonal Cells are a population of A-549 lung adenocarcinoma cells subjected to CRISPR/Cas9-mediated disruption of the CBX8 gene. This polyclonal knockout product consists of a heterogeneous pool of edited cells, collectively exhibiting reduced CBX8 protein expression. The pooled format maintains genetic diversity and provides a robust loss-of-function model for studying CBX8-dependent processes without the need for clonal isolation.
The host A-549 cell line is a widely used model of human non-small cell lung cancer (NSCLC), originally derived from the lung adenocarcinoma of a 58-year-old male. These epithelial cells retain key oncogenic mutations and morphological characteristics of lung adenocarcinoma, making them a standard platform for cancer cell biology, drug sensitivity testing, and signal transduction research.
CBX8 is a core component of Polycomb repressive complex 1 (PRC1), where it binds H3K27me3 via its chromodomain to mediate chromatin compaction and transcriptional silencing. CBX8 functions within a network of interacting partners, including BMI1, RING1B, PCGF2, and PHC1, and is regulated by upstream factors such as E2F transcription factors, MYC, and MAPK signaling. PRC1 complexes directed by CBX8 repress critical downstream targets, including the tumor suppressor CDKN2A and multiple HOX genes. Disruption of CBX8 leads to de-repression of these loci, altering gene expression programs that control cell proliferation and differentiation.
In A-549 cells, loss of CBX8 is expected to impair PRC1-mediated gene silencing, resulting in altered expression of CDKN2A, HOX genes, and other tumor suppressors. This de-repression may influence key malignant properties such as proliferation, migration, and clonogenic potential, providing a model to investigate epigenetic drivers of NSCLC. The system also facilitates exploration of cross-regulation between PRC1 and Wnt/??-catenin signaling in lung adenocarcinoma.
These polyclonal knockout cells are suitable for versatile applications, including functional dissection of Polycomb repressive mechanisms, epigenetic regulation in lung cancer, and drug target validation. They support an array of assays: western blotting and RT-qPCR for expression analysis, ChIP-qPCR for chromatin occupancy, proliferation and migration assays for functional readouts, and RNA-seq for transcriptomic profiling. For lot-specific characterization data, please contact Ascent Research.
